Literature DB >> 236806

Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma.

C Skinner, J Gaddie, K N Palmer.   

Abstract

The cardiac and bronchial effects of AH 5158 and propranolol were compared in a double-blind, placebocontrolled intravenous study on 10 asthmatics. AH 5158, like propranolol, is a non-cardioselective beta-adrenoceptor-blocking drug, but unlike propranolol it also has an alpha-adrenoceptor-blocking action. Both drugs produced equivalent cardiac(beta1) blockade, but propranolol produced bronchoconstriction, whereas AH 5158 did not. Hence the alpha-blocking action of AH 5158 seems to prevent the bronchoconstrictor effects of propranolol in these patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 236806      PMCID: PMC1673027          DOI: 10.1136/bmj.2.5962.59

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man.

Authors:  A J Boakes; E J Knight; B N Prichard
Journal:  Clin Sci       Date:  1971-04       Impact factor: 6.124

2.  The effect of an alpha-adrenergic receptor blocking drug on histamine sensitivity in bronchial asthma.

Authors:  J Gaddie; J S Legge; G Petrie; K N Palmer
Journal:  Br J Dis Chest       Date:  1972-04

3.  The effect of thymoxamine on histamine induced bronchospasm in man.

Authors:  S Bianco; J P Griffin; P L Kamburoff; F J Prime
Journal:  Br J Dis Chest       Date:  1972-01

4.  Dynamic and static lung volumes and blood-gas tensions in bronchial asthma.

Authors:  K N Palmer; M L Diament
Journal:  Lancet       Date:  1969-03-22       Impact factor: 79.321

5.  Effect of a selectivebeta-adrenergic blocker in preventing falls in arterial oxygen tension following isoprenaline in asthmatic subjects.

Authors:  K N Palmer; W F Hamilton; J S Lge; M L Diament
Journal:  Lancet       Date:  1969-11-22       Impact factor: 79.321

6.  A comparison of the effect on airway resistance of a new beta blocking drug, ICI.50,172 and propranolol.

Authors:  A G Macdonald; R S McNeill
Journal:  Br J Anaesth       Date:  1968-07       Impact factor: 9.166

7.  Respiratory effects of acebutolol hydrochloride.

Authors:  W P Leary; A J Coleman; A C Asmal
Journal:  S Afr Med J       Date:  1973-07-21

8.  Effect of alpha-receptor blocking drugs and disodium cromoglyate on histamine hypersensitivity in bronchial asthma.

Authors:  J W Kerr; M Govindaraj; K R Patel
Journal:  Br Med J       Date:  1970-04-18

9.  Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors:  J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

  9 in total
  16 in total

Review 1.  Intrinsic sympathomimetic activity of beta-adrenoceptor blocking agents.

Authors:  G Cocco; F Burkart; D Chu; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

2.  Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects.

Authors:  J G Maconochie; E P Woodings; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

Review 3.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

4.  Failure of enhancement by labetalol of bronchopulmonary effects of histamine in guinea-pigs: independence of alpha-adrenoceptor antagonism.

Authors:  C Clerici; A Harf; I Macquin-Mavier
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

5.  Evaluation of I.V. labetalol for treatment of posttraumatic hyperdynamic state.

Authors:  D R Morel; A Forster; P M Suter
Journal:  Intensive Care Med       Date:  1984       Impact factor: 17.440

Review 6.  Clinical pharmacology of labetalol.

Authors:  D A Richards; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

7.  Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment.

Authors:  G R Bellamy; S N Hunyor; D Roffe; J Massang
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

8.  Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension.

Authors:  M H Frick; P Pörsti
Journal:  Br Med J       Date:  1976-05-01

9.  The use of labetalol in Japan: results of multicentre clinical trials.

Authors:  T Takeda; Y Kaneko; T Omae; K Yoshinaga; Y Masuyama; T Nukada; R Shigiya
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  Comparison of labetalol and propranolol in hypertension.

Authors:  D P Nicholls; M H Husaini; C J Bulpitt; M D Stephens; A G Butler
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.